Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Payables (2016 - 2026)

Ekso Bionics Holdings has reported Payables over the past 13 years, most recently at $2.7 million for Q4 2025.

  • On a quarterly basis, Payables fell 4.32% to $2.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.7 million, a 4.32% decrease, with the full-year FY2025 number at $2.7 million, down 4.32% from a year prior.
  • Payables reached $2.7 million in Q4 2025 per EKSO's latest filing, down from $2.9 million in the prior quarter.
  • The five-year high for Payables was $6.1 million in Q2 2023, with the low at $1.3 million in Q3 2021.
  • The 5-year median for Payables is $3.1 million (2023), against an average of $3.3 million.
  • Peak YoY movement for Payables: surged 235.09% in 2022, then plummeted 44.82% in 2024.
  • Tracing EKSO's Payables over 5 years: stood at $3.1 million in 2021, then soared by 75.76% to $5.5 million in 2022, then plummeted by 43.29% to $3.1 million in 2023, then decreased by 9.53% to $2.8 million in 2024, then dropped by 4.32% to $2.7 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $2.7 million, $2.9 million, and $2.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.